BLCO
Bausch + Lomb Corp.
NYSE · Healthcare · Medical - Instruments & Supplies · CA
$20.68
+3.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.4B | 5.1B | 4.8B | 4.1B | 3.8B |
| Cost of Revenue | 2.2B | 2.3B | 1.9B | 1.6B | 1.5B |
| Gross Profit | 3.2B | 2.8B | 2.9B | 2.5B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | 400.0M | 371.0M | 343.0M | 324.0M | 307.0M |
| SG&A Expense | 2.3B | 2.2B | 2.1B | 1.7B | 1.5B |
| General & Admin Expense | 556.0M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 66.0M | — | 332.0M | 314.0M | 257.0M |
| Total Operating Expenses | 2.7B | 2.6B | 2.8B | 2.4B | 2.0B |
| Cost and Expenses | 5.0B | 4.9B | 4.6B | 4.0B | 3.6B |
| Operating Income (EBIT) | 455.0M | 188.0M | 162.0M | 130.0M | 207.0M |
| Non-Operating | |||||
| Interest Income | 13.0M | 12.0M | 15.0M | 15.0M | 6.0M |
| Interest Expense | 388.0M | 431.0M | 399.0M | 283.0M | 146.0M |
| Net Interest Income | (375.0M) | (419.0M) | (384.0M) | (268.0M) | (140.0M) |
| Other Non-Op Income/Expense | (459.0M) | (505.0M) | (396.0M) | (296.0M) | (134.0M) |
| Non-Operating Income (excl Interest) | 71.0M | 74.0M | (3.0M) | 13.0M | (12.0M) |
| EBT (Pre-Tax Income) | (4.0M) | (317.0M) | (234.0M) | (166.0M) | 73.0M |
| Income Tax Expense | 99.0M | 35.0M | 71.0M | 82.0M | 58.0M |
| Bottom Line | |||||
| Net Income | (111.0M) | (360.0M) | (317.0M) | (260.0M) | 6.0M |
| Earnings from Cont. Ops | (103.0M) | (352.0M) | (305.0M) | (248.0M) | 15.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (111.0M) | (360.0M) | (317.0M) | (260.0M) | 6.0M |
| Per Share | |||||
| Basic EPS | ($0.31) | ($1.02) | ($0.90) | ($0.74) | $0.04 |
| Diluted EPS | ($0.31) | ($1.02) | ($0.90) | ($0.74) | $0.04 |
| Revenue Per Share | $15.14 | $14.42 | $13.62 | $11.83 | $10.77 |
| Shares | |||||
| Basic Shares Outstanding | 357.6M | 353.8M | 351.8M | 350.5M | 350.0M |
| Diluted Shares Outstanding | 361.5M | 353.8M | 351.8M | 350.5M | 350.0M |
| Profitability Metrics | |||||
| EBITDA | 686.0M | 535.0M | 601.0M | 499.0M | 598.0M |
| D&A | 302.0M | 421.0M | 436.0M | 382.0M | 379.0M |
| EBIT | 384.0M | 114.0M | 165.0M | 117.0M | 219.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026